Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C546S176000, C546S177000, C546S276400
Reexamination Certificate
active
07105537
ABSTRACT:
The present invention relates to modulators of the calcium sensing receptor having the formula IwhereinAr1, X, n, R1, R2, R3and Q are as defined herein.
REFERENCES:
patent: 4411890 (1983-10-01), Momany
patent: 5688938 (1997-11-01), Brown et al.
patent: 5763569 (1998-06-01), Brown et al.
patent: 6022894 (2000-02-01), Del Mar et al.
patent: 6031003 (2000-02-01), Nemeth et al.
patent: 6211244 (2001-04-01), Van Wagenen et al.
patent: 6436904 (2002-08-01), Ashwell et al.
patent: 0342613 (1992-11-01), None
patent: 0449011 (1997-10-01), None
patent: WO 89/07110 (1989-08-01), None
patent: WO 89/07111 (1989-08-01), None
patent: WO 93/04081 (1993-03-01), None
patent: WO 94/18959 (1994-09-01), None
patent: WO 97/37967 (1997-10-01), None
patent: WO 98/45255 (1998-10-01), None
patent: WO 99/51241 (1999-10-01), None
patent: WO 99/51569 (1999-10-01), None
patent: WO 00/45816 (2000-08-01), None
Delmas, P. and Meunier, P., “The Management of Paget's Disease of Bone,” N. Engl. J. Med., vol. 336(8), pp. 558-566 (Feb. 20, 1997) at p. 560, col. 2, lines 24-28; p. 561, Table 1; and p. 563, col. 1, lines 10-22.
Ashwell et al., STN International (2006) HCAPLUS Database, Columbus, OH, Accession No.: 2000:513717.
Brown, E.M. et al., “Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid”, Nature, vol. 366, pp. 575-580 (1993).
Bundgaard, H., Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Edwards, J.P. et al., “Nonsteroidal Androgen Receptor Agonists Based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one”, Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 1003-1008 (1999).
Gowen, M. et al., “Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats”, The Journal of Clinical Investigation, vol. 105, No. 11, pp. 1595-1604 (2000).
Greene, T.W. et al., Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, Inc., publ., pp. xi-xii (table of contents) (1999).
Hamann, L.G. et al., “Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)”, J. Med. Chem., vol. 42, No. 2, pp. 210-212 (1999).
Hudlicky, M., Oxidations in Organic Chemistry: ACS Monograph 186, American Chemical Society, publ., pp. ix-xiii (table of contents) (1990).
Larock, R.C., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, Inc., publ., pp. xiii-xxviii (table of contents) (1989).
Neer, R.M. et al., “Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis”, The New England Journal of Medicine, vol. 344, No. 19, pp. 1434-1441 (2001).
Wermuth, C.G. et al., Chapter 31:, “Designing Prodrugs and Bioprecursors I: Carrier Prodrugs”, The Practice of Medicinal Chemistry, Academic Press, publ., Wermuth, C.G., ed., pp. 671-696 (1996).
Whitfield, J.F. et al., “Parathyroid Hormone, Its Fragments and Their Analogs for the Treatment of Osteoporosis”, Treat. Endocrinal., vol. 1, No. 3, pp. 175-190 (2002).
Zaragoza, F. et al., “(Cyanomethyl)trialkylphosphonium Iodides: Efficient Reagents for the Intermolecular Alkylation of Amines with Alcohols in Solution and on Solid Phase”, J. Org. Chem., vol. 66, No. 7, pp. 2518-2521 (2001).
Betts, M.J. et al., “ ‘ Hidden’ axial chirality as a stereodirecting element in reactions involving enol(ate) intermediates. Part 2. Cyclisation reactions of methyl (4R)-3-(2-diazo-3-oxobutanoyl)-1,1-dioxo-1λ6,3-(and 1-oxo-1λ4,3-) thiazolidine-4-carboxylates”, J. Chem. Soc., Perkin Trans. 1, pp. 1067-1072 (1999).
Florvall, L. et al., “Selective Monoamine Oxidase Inhibitors. 3. Cyclic Compounds Related to 4-Aminophenethylamine. Preparation and Neuron-Selective Action of Some 5-(2-Aminoethyl)-2,3-dihydroindoles”, J. Med. Chem., vol. 29, No. 8, pp. 1406-1412 (1986).
Greenstein, J.P. et al., Chemistry of the Amino Acids, vol. 3, Robert E. Krieger Publishing Company, Inc., publ., pp. v-xiii (table of contents) (1984.
Lee, D.G., Chapter 11: “Phase Transfer Assisted Permanganate Oxidations”, Oxidation in Organic Chemistry, Part D, Academic Press, publ., Trahanovsky, W.S., ed., pp. 147-204 (1982).
Moed, H.D. et al., “Synthesis of β-phenyl-ethylamine Derivaties. III) Bronchodilators”, Recl. Trav. Chim. Pays-Bas, vol. 74; pp. 919-936 (1955).
Nichols, D.E. et al., “Effects of Certain Hallucinogenic Amphetamine Analogues on the Release of [3H]Serotonin from Rat Brain Synaptosomes”, J. Med. Chem., vol. 25, No. 5, pp. 530-535 (1982).
Norris, R.K. et al., “Kinetics and Stereochemistry of Elimination of Nitrous Acid from 1-p-Nitrophenyl-2-nitroethyl Derivatives”, Aust. J. Chem., vol. 39, pp. 281-294 (1986).
Stewart, R., Chapter 1: “Oxidation by Permanganate”, Oxidation in Organic Chemistry, Part A, Academic Press, publ., Wiberg, K.B., ed., pp. 1-68 (1965).
Heindl et al., Enantiospecific synthesis and receptor binding of novel dopamine receptor ligands employing natural 4-hydroxyproline as a practical and flexible building block, Tetrahedron: Asymmetry, Oct. 17, 2003, vol. 14, pp. 3153-3172.
Corte James R.
Dickson, Jr. John K.
Gavai Ashvinikumar V.
Gungor Timur
Roberge Jacques Y.
Bristol--Myers Squibb Company
Freistein Andrew B.
Rodney Burton
Saeed Kamal A.
LandOfFree
2-substituted cyclic amines as calcium sensing receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-substituted cyclic amines as calcium sensing receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-substituted cyclic amines as calcium sensing receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3611599